References
- Vallarola A, Sironi F, Tortarolo M, et al. RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. J Neuroinflammation. 2018;15:65.
- Khasnavis S, Roy A, Ghosh S, et al. Protection of dopaminergic neurons in a mouse model of Parkinson’s disease by a physically-modified saline containing charge-stabilized nanobubbles. J Neuroimmune Pharmacol. 2014;9:218–32.
- Rangasamy SB, Ghosh S, Pahan K. RNS60, a physically-modified saline, inhibits glial activation, suppresses neuronal apoptosis and protects memory in a mouse model of traumatic brain injury. Exp Neurol. 2020;328:113279.
References
- Camu W, Mickunas M, Veyrune J-L, et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double-blind, placebo-controlled trial. eBiomedicine. 2020;59: 102844. 10.1016/j.ebiom.2020.102844
References
- Bede P, Bokde A, Elamin M, et al. Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry. 2013;84:766–73.
- Sala A, Iaccarino L, Fania P, et al. Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. Eur J Nucl Med Mol Imaging. 2019;46:1117–31.
References
- Klim JR, Williams LA, Limone F, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167–79.
- Guerra San Juan I, Nash LA, Smith KS, Leyton-Jaimes MF, et al. Loss of mouse Stmn2 function causes motor neuropathy. Neuron 2022;110:1671–88.e6.
- Theunissen F, Anderton RS, Mastaglia FL, et al. Novel STMN2 variant linked to amyotrophic lateral sclerosis risk and clinical phenotype. Front Aging Neurosci. 2021;13:658226.
- Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7:1–11.
- Huang X, Roet KCD, Zhang L, et al. Human amyotrophic lateral sclerosis excitability phenotype screen: target discovery and validation. Cell Rep. 2021;35:109224.
- Wainger BJ, Macklin EA, Vucic S, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78:186–96.
- Boivin B, Roet KCD, Huang X, et al. Mol Biol Cell 2022;33:ar54.
References
- Premasiri AS, Gill AL, Vieira FG. Type I PRMT inhibition protects against C9ORF72 arginine-rich dipeptide repeat toxicity. Front Pharmacol. 2020;11:569661.
- Gill AL, Premasiri AS, Vieira FG. Hypothesis and theory: roles of arginine methylation in C9orf72-Mediated ALS and FTD. Front Cell Neurosci. 2021;15:633668.
- Du Z-W, Chen H, Liu H, et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat Commun. 2015;6:6626.
References
- Benatar M, Wuu J, McHutchison C, et al. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain. 2022;145:27–44.
- Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130–9.
- Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo-controlled trial of Tofersen initiated in clinically presymptomatic SOD1 carriers: The ATLAS Study. Neurotherapeutics 2022. doi:10.1007/s13311-0220-01237-4
- Benatar M, Granit V, Anderson PM, et al. Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity. Brain. 2022. doi:10.1093/brain.awac185
References
- Camu W, Mickunas M, Veyrune J-L, et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double-blind, placebo-controlled trial. eBioMedicine 2020;59:102844. 10.1016/j.ebiom.2020.102844
- Giovannelli I, Bayetti N, Brown A, et al. Brain Comms 2021;3:fcab141
References
- Tibshirani M, Zhao B, Gentil BJ, Minotti S, Marques C, Keith J, et al. Dysregulation of chromatin remodelling complexes in amyotrophic lateral sclerosis. Hum Mol Genet. 2017;26:4142–52.
- Kuta R, Larochelle N, Fernandez M, Pal A, Minotti S, Tibshirani M, et al. Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models. Cell Stress Chaperones. 2020;25:173–91.
References
- Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016;539:197–206.
- Eastel JM, Lam KW, Lee NL, et al. Application of NanoString technologies in companion diagnostic development. Expert Rev Mol Diagn. 2019;19:591–8.
References
- Bunton-Stasyshyn RKA, Saccon RA, Fratta P, Fisher EMC. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. Neuroscientist. 2015;21:519–29.
- Wagner L, Rechtman L, Jordan H, et al. State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:128–34.
- Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
- National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet.
Reference
- Andersen P, Abrahams S, Borasio G, et al. Eur J Neurol 2012;19:360–75.